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Anti-microtubule agents bind to tubulin or microtubules and
inhibit cell replication by acting on the mitotic spindle (Wilson
and Jordan, 1995). Vinca alkaloids depolymerize microtubules;
taxoids induce the formation of stable, non-functional micro-
tubular bundles in interphase cells. These agents are among the
most effective anticancer drugs, in particular the taxoids paclitaxel
(Taxol®) and docetaxel (Taxotere®) for treatment of advanced
ovarian and breast carcinomas. They also show activity against
other carcinomas (Rowinsky et al, 1992; Dieras et al, 1996;
McGuire et al, 1996). Several promising antimitotic compounds
have been characterized, particularly discodermolide and
epothilones, which are taxol-like compounds, and cryptophycins
and dolastatins, which are depolymerizing agents (De Arruda et al,
1995; Jordan and Wilson, 1998). Moreover, analogues of pacli-
taxel and docetaxel display potential clinical importance. Clinical
evaluation is in progress for some of these novel compounds.
However, drug resistance hinders the successful use of anticancer
drugs. The best understood mechanism of resistance to cytotoxic
drugs including anti-microtubule agents is the MDR phenotype
mediated by the multidrug transporter P-glycoprotein (P-gp)
(Horwitz et al, 1993). Other possible mechanisms of specific resis-
tance to anti-microtubule agents concern alterations in micro-
tubule composition or dynamics. Alterations in a- and b-tubulin
subunits have been described in both human and non-human pacli-
taxel-resistant cell lines (Schibler and Cabral, 1986; Ranganathan
et al, 1998). However, mutations or changes in the expression
of tubulin subunits in human tumour cells are poorly defined.
Furthermore, the dynamics of microtubules assembled from
purified  b-tubulin isotypes differs in vitro, which influences the
sensitivity to anti-microtubule drugs (Derry et al, 1997).
Human adenocarcinoma is often composed of both undifferenti-
ated and differentiated cells. The differentiation status is one of the
major prognostic factors. The undifferentiated cells proliferate and
are highly sensitive to anticancer drugs; on the contrary, differenti-
ated cells are classically less sensitive to chemotherapy, even if
they display a less aggressive behaviour because of their low rate
of proliferation. For these reasons, the human colon adenocarci-
noma HT29-D4 cell line is particularly suitable to study the micro-
tubule changes according to the phenotype of cell differentiation.
Indeed, HT29-D4 cells grown with glucose proliferate and are
undifferentiated; with galactose, they differentiate into an entero-
cyte-like polarized cell (Fantini et al, 1986; Rognoni et al, 1998).
Stability of microtubules has been implicated in the establish-
ment of polarity in neuronal cells and fibroblasts (Baas and Black,
1990; Gurland and Gundersen, 1995). Few studies were conducted
on polarized epithelial cell models such as MDCK and Caco-2
(Simons and Wandinger-Ness, 1990). Microtubules in polarized
MDCK cells were more resistant to depolymerization than micro-
tubules in non-polarized cells (Wadsworth and Bottaro, 1996).
Stable microtubules often contain post-translationally modified
tubulin, but acetylation and detyrosination are the result rather
than the cause of microtubule stability (Bulinski and Gundersen,
1991). Other factors, such as mitogen-activated proteins (MAPs)
and tubulin isotypes, are also involved in the events of microtubule
stabilization (Matus, 1988; Falconer et al, 1992). Dynamic
instability is cell type-specific (Cassimeris, 1993; Shelden and
Wadsworth, 1993). Moreover, the molecular mechanisms respon-
sible for the control of microtubule dynamic behaviour during cell
growth and differentiation are largely unknown.
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Summary The human colon adenocarcinoma HT29-D4 cell line is an interesting model for studies on epithelial cell differentiation.
Undifferentiated cells are malignant proliferating cells, whereas differentiated cells act like epithelial polarized cells. In the present study, we
first characterized the action of taxoids on the microtubular network of HT29-D4 cells according to the state of differentiation. Microtubular
bundles were found in undifferentiated cells but not in differentiated cells, even with 500-fold higher taxoid concentrations for 96 h. This finding
led us to study changes in microtubules according to the polarity status of the cell. E-MAP-115 was expressed only in differentiated cells;
expression of b-tubulin isotypes was altered in them relative to undifferentiated cells. Classes I, II, III, IVa and IVb isotypes were expressed in
both phenotypes; however, differentiated epithelial cells displayed a specific increase in class III b-tubulin. Thus, the increase in expression of
this b-tubulin isotype in differentiated cells is not restricted to neuronal cells. Moreover, these expression changes may reflect a higher stability
of microtubular network in differentiated cells, which may explain the lower activity of anti-microtubule agents, independently of the mitotic
process. These results indicate that the composition of microtubules should be considered as one of the criteria involved in the response of
tumour cells to chemotherapy with anti-microtubule agents.
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in undifferentiated cells, we sought to investigate the changes in
microtubules linked with the polarity status of the cells. Beside
detyrosination of a-tubulin, differentiated cells displayed expres-
sion of E-MAP-115 and a specific increase in class III b-tubulin
isotype. These variations may be involved in the difference of
response to taxoids on HT29-D4 cells according to this differenti-
ation state, independently of mitotic process.
MATERIALS AND METHODS
Cell culture and differentiation
Because of cellular heterogeneity of the original HT29 cell line,
the HT29-D4 clone was isolated by limiting dilution technique.
Undifferentiated HT29-D4 cells (HT29-D4 Glu) were routinely
grown in Dulbecco’s modified Eagle’s medium (DMEM)
(Biowhittaker, Vervier, Belgium) containing 25 mM glucose (Glu
medium). To induce the differentiation of HT29-D4 cells, glucose
was replaced by galactose (Gal medium). The detailed conditions
of HT29-D4 cell culture were published elsewhere (Fantini et al,
1986, 1989). The doubling time was 20 ± 2 h in Glu medium.
Differentiated HT29-D4 Gal cells were limited to two subcultures.
Drugs
Paclitaxel was obtained from Sigma (St Louis, MO, USA).
Docetaxel was a gift from Rhône Poulenc Rorer (Paris, France).
Stock solutions of drugs (0.01 M) were made in dimethyl
sulphoxide (DMSO) and were stored at –20°C. The working
solutions were diluted in culture medium; the highest concentra-
tion of DMSO was 0.2% (v/v). [3H]paclitaxel and [14C]docetaxel
were from Moravek Biochemicals Inc. (Brea, CA, USA) and
Commissariat à l’Energie Atomique (Saclay, France) respectively.
Transmission electron microscopy
Cells were fixed in situ with 2.5% glutaraldehyde in 0.1 M sodium
phosphate buffer pH 7.3 for 1 h, washed in the same buffer with
6.84% saccharose, post-fixed in 1% osmium tetroxide, dehydrated
in ethanol and embedded in Epon. Sections were observed with a
Jeol 100 C electron microscope.
Carcinoembryonic antigen measurement
The release of carcinoembryonic antigen (CEA) into the cell
culture medium was determined with a commercially available
CEA–EIA kit (Abbot Laboratories, Chicago, IL, USA).
Immunofluorescence microscopy
Cells grown on glass coverslips were rinsed three times with phos-
phate-buffered saline (PBS), lysed with 0.5% Triton X-100, fixed
with 3.7% formaldehyde, and stained with anti-a-tubulin and anti-
mouse immunoglobulin, fluorescein-linked whole antibody (Ab)
(Amersham, UK) as previously described (Garcia et al, 1994). For
staining with anti-CEA (Biosys, Compiegne, France) and anti-b1
integrin (Immunotech-Coulter, Marseille, France), cells were
blocked, incubated for 1 h at 4°C with specific Ab and fixed with
3% paraformaldehyde. They were stained with a second anti-
mouse immunoglobulin Ab coupled to fluorescein and mounted on
glass slides in a solution containing 90% of glycerol and 10% of
PBS.
Cell drug accumulation
Total binding of [3H]paclitaxel or [14C]docetaxel to cells was deter-
mined according to the technique of Manfredi and Horwitz (1984).
Protein determination and radioactivity were measured as previ-
ously described (Garcia et al, 1994).
Evaluation of total and cytoskeletal tubulin protein
For quantification of total tubulin protein, cells were washed twice
in cold PBS and lysed at 90°C in lysis buffer containing Tris–HCl
pH 6.80, 2.5% of sodium dodecyl sulphate (SDS), 5% of
mercaptoethanol, and 10% of glycerol. For quantification of
cytoskeletal tubulin protein, cells were washed twice in PEM/PEG
buffer containing 100 mM Pipes, 1 mM ethyleneglycol-bis-(b
aminoethyl ether) N,N,N¢,N¢-tetraacetic acid (EGTA), 1 mM
magnesium chloride and 4% of polyethylene glycol (PEG) 8000.
Soluble proteins were extracted for 90 s in PEM/PEG buffer
containing 0.5% of Triton X-100 and 10–3 M GTP and lysed in the
lysis buffer. All buffers contained protease inhibitors 1 mM
phenylmethylsulphonyl fluoride (PMSF), 50 mg ml–1 leupeptin,
1 mg ml–1 pepstatin, 1 mg ml–1 trypsin inhibitor and 20 mg ml–1
aprotinin (Sigma, St Louis, MO, USA). Bio-Rad protein assay dye
reagent was used to determine the protein concentration of lysates.
Western blotting
Equal amounts of total or cytoskeletal proteins were prepared in
SDS, boiled and then applied to a 10% acrylamide-SDS running
gel. Proteins were blotted onto Hybond-C extra nitrocellulose
membrane (Amersham, UK) with an Electrophoretic Transfer Cell
apparatus (Bio-Rad Laboratories, CA, USA). Equal loadings and
efficient transfer of proteins were confirmed by staining the
membrane with ponceau S red before immunodetection. The
membrane was blocked for 3 h with PBS containing 5% dried non-
fat milk powder and 0.1% Tween-20 and then incubated overnight
at 4°C with primary Abs. The membrane was incubated for 1 h in
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Table 1 Intracellular[3H] paclitaxel and [14C]docetaxel in HT29-D4 Glu and
Gal cells. Each point shows the mean of three independent experiments
(± s.d.)
Intracellular drug
(pM mg–1 protein)
Drug concentration HT29-D4 HT29-D4
(nM) Glu cells Gal cells
[3H] paclitaxel 50 118 ± 9 144 ± 7
100 204 ± 11 265 ± 6
500 397 ± 106 644 ± 37
1000 561 ± 170 959 ± 44
2000 1010 ± 180 1635 ± 92
[14C] docetaxel 50 15 ± 3 37 ± 1
100 45 ± 1 122 ± 7
500 118 ± 1 249 ± 14
1000 147 ± 17 330 ± 28
2000 196 ± 3 491 ± 70secondary specific Ab conjugated with peroxydase (Amersham),
washed, and processed in enhanced chemiluminescence (ECL)
reagent (Amersham). Densitometric quantification was performed
using TRAITIMA, a homemade software. Western blots were
obtained from at least three independent experiments using sepa-
rate cultures.
The primary antibodies for immunoblotting, mouse monoclonal
antibody (mAb) anti-E-MAP-115 and rabbit anti-detyrosinated
tubulin (Glu Tubulin), were generously provided by Masson and
Kreis respectively; rabbit polyclonal Ab to MAP4 by Bulinski and
mouse mAb to class III b-tubulin isotype by Frankfurter. Anti-a-
tubulin Ab (N356) was from Amersham, anti-b-tubulin (T4026),
anti-a-tyrosinated (T9028) and anti-a-acetylated (T6793) Abs
from Sigma, and anti-class IV b-tubulin isotype (MU 178-UC)
from Biogenex (San Ramon, CA, USA). Secondary anti-mouse
(NA931) and anti-rabbit (NA934) immunoglobulins, horseradish
peroxidase were from Amersham.
RNA isolation and RT-PCR analysis
Total cellular RNA was extracted with the RNAXEL kit (Eurobio,
Les Ullis, France) (Chomczinski and Sacchi, 1987). RNA was
quantitated by absorbance at 260 nm. Approximately 1 mg of total
RNA was used for reverse transcription (RT) reaction with random
primers. We then amplified the various tubulin isotype genes and
b2 microglobulin (b2M), the internal standard, with Taq poly-
merase (Appligen, Illkirch, France).
Primer sequences were:
b2M (sense): 5¢ CCGACATTGAAGTTGACTTAC 3¢
b2M (antisense): 5¢ ATCTTCAAACCTCCATGATG 3¢
M40 (class I) (sense): 5¢ CCATACATACCTTGAGGCGA 3¢
M40 (class I) (antisense): 5¢ GCCAAAAGGACCTGAGCGAA 3¢
b9 (class II) (sense): 5¢ CGCATCTCCGAGCAGTTCAC 3¢
b9 (class II) (antisense): 5¢ TCGCCCTCCTCCTCCTCGA 3¢
b4 (class III) (sense): 5¢ ATGAGGGAAATCGTG 3¢
b4 (class III) (antisense): 5¢ AAAGGCCCCTGAGCGGACACT 3¢
b5 (class IVa) (sense): 5¢ TCTCCGCCGCATCTTCCA 3¢
b5 (class IVa) (antisense): 5¢ TCTGGGGACATAATTTCCTC 3¢
b2 (class IVb) (sense): 5¢ GACGGTCGGTTGTAGCACTCTG 3¢
b2 (class IVb) (antisense): 5¢ CAGCACCACTCTGACCGAAAA 3¢.
Class I, III, IVa and IVb b-tubulin primers were designed to
span introns. In the case of the class II b-tubulin isotype, sequence
was obtained from the EMBL GeneBank (accession number X7
and 9353), and using the peptide sequence previously reported by
Cowan et al (1986). In separate experiments the presence of
tubulin pseudogenes was analysed by performing PCR directly
on the RNA, and by digesting RNA with DNAase before cDNA
synthesis.
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Table 2 Expression ratios of total and polymerized a- and b-tubulin, and
post-translational modified a-tubulin in HT29-D4 Glu and HT29-D4 Gal cells
Ratio Glu/Gala
Total tubulin Polymerized tubulin
a-tubulin 1.6 ± 0.3 1.1 ± 0.1
Tyrosinated a-tubulin 2.4 ± 0.5 1.1 ± 0.2
Detyrosinated a-tubulin – 0.5 ± 0.1
Acetylated a-tubulin 1.6 ± 0.2 1.2 ± 0.3
b-tubulin 1.6 ± 0.2 0.8 ± 0.2
aRatios are expressed as the densitometric value of protein in HT29-D4 Glu
cells divided by the densitometric value of protein in HT29-D4 Gal cells.
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Figure 1 Transmission electron micrographs of HT29-D4 cells. HT29-D4
Glu cells (A) grown in Glu medium are undifferentiated and form a non-
polarized cell multilayer. HT29-D4 Gal cells (B) grown in Gal medium for 30
days are organized into a polarized monolayer with apical brush border (BB)
and tight junction (TJ). D: desmosome, IS: intercellular space, N: nucleus.
Bar = 3.3 mmPCR was carried out in a Perkin-Elmer system 2400 thermo-
cycler. The reaction conditions included an initial cycle of denatu-
ration at 94°C for 2 min, followed by 25–35 cycles of denaturation
at 94°C for 10 s, annealing at 50°C (class I, II, IVa and IVb) or
55°C (class III) for 30 s, and extension at 72°C for 30 s. The
amplified products were separated by electrophoresis on a 2%
agarose gel. The DNA bands were visualized by ethidium bromide
staining, and the image was digitized by an Appligen Imager. Gene
expression was normalized to b2M transcript; this was noted REL
for relative expression level: REL = densitometric value of studied
gene/densitometric value of b2M.
RESULTS
Cell differentiation
Electron microscopy showed that HT29-D4 Glu, i.e. undifferenti-
ated cells, formed a non-polarized cell multilayer (Figure 1A)
whereas HT29-D4 Gal cells showed morphological changes char-
acteristic of the differentiated phenotype such as cell monolayer
with tight junctions and an apical brush border (Figure 1B). CEA
was faintly expressed at the surface of HT29-D4 Glu cells; for
HT29-D4 Gal cells, it was expressed at the apical side and released
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Figure 2 Indirect immunofluorescence staining of microtubular network with a-tubulin mAb. Undifferentiated HT29-D4 Glu (A) and differentiated HT29-D4 Gal
(C) control cells; HT29-D4 Glu cells treated with paclitaxel 50 nM for 6 h (B) and HT29-D4 Gal cells treated with paclitaxel 1 mM for 24 h (D). Bundles (arrow)
were detected only in paclitaxel-treated undifferentiated HT29-D4 Glu cells. Bar = 10 mmin a concentration dependent manner (data not shown). b1 integrin,
a polarity marker selectively expressed at the baso-lateral side of
differentiated cells, showed no immunofluorescence in HT29-D4
Gal cells (data not shown).
Activity of taxoids according to the cell phenotype
Modification of microtubular network
Paclitaxel and docetaxel induced a concentration- and time-depen-
dent formation of bundles in HT29-D4 Glu cells (10–1000 nM,
4–6 h), whereas no bundles were observed in HT29-D4 Gal cells
even for contact times as long as 96 h (Figure 2).
Intracellular drug concentration
Intracellular paclitaxel and docetaxel concentrations, expressed in
picomoles per milligram of protein, were twofold higher in HT29-
D4 Gal cells than in HT29-D4 Glu cells (Table 1).
Modifications of the microtubular network according to
the cell phenotype
Cell tubulin content
Western immunoblots from at least three independent experiments
issued from separate cultures are analysed in Table 2. The two
phenotypes of HT29-D4 cells contained the same amount of poly-
merized a-tubulin whatever the polarity status, whereas the total
cell tubulin content was significantly higher in undifferentiated
HT29-D4 Glu cells. Similar results were obtained by quantifica-
tion of b-tubulin. Total tyrosinated a-tubulin was largely more
expressed in HT29-D4 Glu cells; on the contrary detyrosinated a-
tubulin was twofold higher in microtubules isolated from HT29-
D4 Gal cells. The amount of acetylated a-tubulin in microtubules
was unchanged.
Isotypes of b-tubulin
b-tubulin transcripts were first analysed by RT-PCR. Isotype
content was normalized to b2M content (Figure 3A). HT29-D4
Gal cells displayed much more class III b-tubulin isotype than
HT29-D4 Glu cells (PCR ratio Gal/PCR ratio Glu = 1.7 ± 0.50),
contrary to class I, II, IVa and IVb b-tubulin isotypes (Figure 3B).
By immunoblotting, overexpression of class III b-tubulin isotype
in HT29-D4 Gal cells was confirmed at the protein level whereas
the class IV b-tubulin protein content was lower in HT29-D4 Gal
cells than in HT29-D4 Glu cells (Figure 3C).
MAP
Note that E-MAP-115 was very slightly expressed in HT29-D4
Glu cells and significantly increased in the differentiated pheno-
type (Figure 4). The expression of E-MAP-115 was correlated
with the cell polarity evaluated with CEA release. E-MAP-115
was expressed at the beginning of the differentiation process and
then it did not vary while polarity was established (from day 19).
No variation was detected in the expression of MAP4 by using
immunodetection with mAb (Figure 4).
DISCUSSION
The model HT29-D4 cell line issued from human colon adeno-
carcima cells cloned by the limiting dilution technique leads to a
homogeneous cell population. After 1 month of galactose treat-
ment, cell differentiation was complete, as shown by ultrastruc-
tural observations and expression of typical polarity markers.
We have previously shown that the cytotoxicity of anti-micro-
tubule agents on HT29-D4 cells differed markedly according to
the differentiation status (Carles et al, 1998). In the present study,
we first characterized the action of taxoids at the microtubular
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Figure 3 (A,B) b-tubulin isotypes in HT29-D4 Glu cells and HT29-D4 Gal
cells were analysed by RT-PCR. b2M (220 pb) was used as an endogenous
control. PCR products showed significant increases in bI (288 pb), bII
(189 pb), bIVa (271 pb), bIVb (342 pb) transcripts in HT29-D4 Glu cells
whereas bIII (243 pb) transcripts were lower than those of HT29-D4 Gal cells.
(A) An example of such experiments. (B) b-tubulin isotypes in HT29-D4 Gal
cells were quantified and expressed comparatively to their amount arbitrary
evaluated at 100% in HT29-D4 Glu cells. (C) Western blot analysis of
proteins isolated from HT29-D4 Glu and HT29-D4 Gal cells. Total cell
lysates were separated on 10% polyacrylamide gels and stained with class III
and class IV b-tubulin mAbs. The images show a marked increase in the
class III b-tubulin isotype and a decrease in the class IV-b-tubulin isotype in
HT29-D4 Gal cells
123456
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Figure 4 Western blot analysis of E-MAP115 and MAP4 in HT29-D4 Glu
cells (lane 1) and during the course of the differentiation at days 14 (lane 2),
19 (lane 3), 26 (lane 4), 30 (lane 5), 35 (lane 6). Establishment of polarity,
assessed by CEA release was apparent from day 19Microtubular network and cell differentiation 1167
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level on both phenotypes independently of the mitotic process.
Microtubular bundles were seen in undifferentiated cells (HT29-
D4 Glu) after a 4–6 h treatment with paclitaxel or docetaxel. This
duration of treatment was too short to induce a mitotic block. In
similar conditions, and even for 500-fold higher concentrations of
the two drugs and longer treatment, bundle formation was never
observed in differentiated cells (HT29-D4 Gal). This phenomenon
cannot be due to a difference in intracellular drug concentration
because it was higher in HT29-D4 Gal cells, probably because of
a larger membrane area or a modification in its composition.
Moreover HT29-D4 does not express the mdr-1 gene (Dimanche-
Boitrel et al, 1993). The striking contrast in sensitivity of these two
phenotypes to taxoids led us to study the changes in microtubular
network according to the differentiation process.
Immunoblots show that microtubular protein amount was iden-
tical for both phenotypes whereas the total tubulin was higher in
HT29-D4 Glu cells. As expected, the analysis of the post-transla-
tional modifications showed a twofold higher expression of de-
tyrosinated a-tubulin in microtubules isolated from HT29-D4 Gal
cells whereas tyrosinated tubulin was expressed more in HT29-D4
Glu cells. These results suggest that microtubules in non-polarized
HT29-D4  Glu cells may be highly dynamic since tyrosinated
tubulin dimers are predominant, and that the microtubule turnover
is largely decreased during differentiation, may be because the
microtubular network is more stable. Acetylation, another post-
translational modification, does not seem involved in the differen-
tiation process of HT29-D4 cells. However, it cannot be excluded
that acetylation may modify discrete regions along stable micro-
tubules. This modification may be too slight to be quantitatively
detected by Western blotting.
Our results indicate that the class I, II, III, IVa and IVb isotypes
were expressed in HT29-D4 cells whatever the differentiation pheno-
type. With the exception of class III b-tubulin isotype, the isotypes
were expressed more in HT29-D4 Glu cells than in HT29-D4 Gal
cells but their relative amount did not differ significantly from that of
the total tubulin. Since their expression varies according to tubulin
level, it appears that these variations are not involved in the polarity
status. Interestingly, the class III b-tubulin isotype mRNA was
expressed at low level in HT29-D4 Glu cells and was increased 1.7-
fold in differentiated enterocyte-like cells. The overexpression of
class III b-tubulin isotype was confirmed at the protein level.
Furthermore, the change in expression of b-III isotype, which is
much greater at the protein level than at mRNA level, suggests that
microtubules from ab-III are stable in differentiated cells.
We demonstrate that the increase in class III b-tubulin isotype is
linked to the differentiation process in epithelial cells, as reported
for differentiated neuronal cells (Gard and Kirshner, 1985; Joshi
and Cleveland, 1989). Little is available on the tubulin isotype
composition of normal or tumour cells; moreover, functional differ-
ences between isotypes that may be generalized to a variety of cell
models have not been identified (Luduena, 1993). Furthermore, b-
tubulin isotypes may undergo post-translational modifications like
glutamylation (Alexander et al, 1991; Rudiger et al, 1992; Mary et
al, 1994) or phosphorylation in the carboxy terminal domain that is
functionally important for the interaction with MAPs.
Other factors such as MAPs are involved in the events of micro-
tubule stabilization (Matus, 1988; Hirokawa, 1994). One could
expect epithelial cell-specific MAPs to be involved in microtubule
stabilization during epithelial cell polarization. MAP4 is the predom-
inant MAP of non-neuronal cells in mammalian proliferating and
differentiating cells (Bulinski and Borisy, 1979). E-MAP-115,
predominantly expressed in cells of epithelial origin, may be another
candidate for a protein regulating microtubule stability and reorgani-
zation during cell polarization, as shown by the strong increase in
labelling in Caco-2 polarized cells (Masson and Kreis, 1993). We
quantified the expression of MAP4 and E-MAP-115 during the
polarization process. No variation in the expression of MAP4 was
observed during HT29-D4 cell differentiation, suggesting that MAP4
does not play a significant role in this process. This data confirms that
removal of MAP4 from microtubules with a blocking Ab in vivo
does not modify the phenotype at the cellular level (Wang et al,
1996). E-MAP-115 was expressed at very low levels in undifferenti-
ated cells, but was largely increased after the beginning of the
polarity process, before CEA was released and the cell monolayer
was established. Consequently, E-MAP-115 is involved in the initial
events of polarization in HT29-D4 cells, as previously reported for
the colon Caco-2 cell line (Masson and Kreis, 1995).
Altogether, our results show two major differences in the micro-
tubular network of HT29-D4 cells according to the cell phenotype:
overexpression of class III b-tubulin isotype and E-MAP-115 in
microtubules in differentiated cells. Each of these changes may
contribute to a higher stability of microtubular network in differ-
entiated cells, beside detyrosination of a-tubulin. Indeed, E-MAP-
115 is involved in stabilizing microtubules in cells as shown in
fibroblasts transfected with E-MAP-115 cDNA. Moreover, b-
tubulin isotype composition can regulate microtubule dynamics,
as demonstrated in vitro with ab-III dimers. We also suggest that
the stabilizing function of E-MAP-115 is strengthened by the over-
expression of class III b-tubulin isotype. Consequently, micro-
tubule dynamics may be reduced in differentiated cells, thereby
inhibiting the activity of anti-microtubule agents independently of
the mitotic process. Microtubules from  a-bIII dimers display a
mean shortening rate lower than that of unfractionated micro-
tubules and they are less sensitive to paclitaxel (Derry et al, 1997).
Moreover, an increase in the class III b-tubulin isotype has been
involved in tumour cells resistant to paclitaxel (Kavallaris et al,
1997; Ranganathan et al, 1998). Our data are of particular interest
in cancer therapy because of the high frequency of human tumours
of epithelial origin and because the differentiation status is one of
the major prognostic factors. Moreover, the present report indi-
cates that the microtubule network may influence the activity of
anti-microtubule agents. The chemosensitivity of tumours varies
according to the phenotype of cell differentiation; it is noteworthy
that proliferating status is often associated with a higher sensitivity
to anticancer drugs. Epithelial tumours are often heterogeneous
regarding to their differentiation phenotypes. Our results suggest
that the most differentiated cells, via alteration of microtubule
network, might promote the emergence of clinical resistance
against anti-microtubule agents, when used at conventional doses.
Thus, the biochemical composition of microtubules should be
considered one of the criteria involved in the response of tumour
cells to chemotherapy with these drugs. Furthermore, since HT29-
D4 cells display a selective increase in the class III b-tubulin
isotype in the differentiated phenotype, this model will help to
further investigate the functional role of this isotype, which has not
yet been clearly defined.
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